Miles Miller
Has grant
Research Interests
Make your next move.
Prepare your application
Review drafts before you send them.
Explore related searches
Recent Grants
Grant: Open
Imaging radiation-enhanced drug delivery for safer and more effective chemoradiotherapy
Open Date: 2025-03-11
Close Date: 2030-02-28
Grant: Open
Expanding the therapeutic window of chemoradiation through radiation-responsive nanoparticle drug depots
Open Date: 2025-03-11
Close Date: 2030-02-28
Grant: Close
Molecular profiling of global tissue dynamics at sub cellular resolution
Open Date: 2022-09-20
Close Date: 2026-07-31
Grant: Close
Dissection of in situ myeloid signaling using image-guided synthetic control
Open Date: 2020-09-04
Close Date: 2025-05-31
Grant: Close
Single Cell In Vivo Imaging Technology to Analyze Taxane Nano Formulations in Breast Cancer
Open Date: 2018-07-01
Close Date: 2021-06-30
Articles (8)
Heterogeneity of cancer-associated fibroblasts (CAFs) has emerged as a critical clinical challenge that undermines the efficacy of cancer therapies in desmoplastic tumours such as pancreatic ductal adenocarcinoma (PDAC). From a nanomedicine perspective, the ability to selectively modulate CAF populations, myofibroblastic CAF (myCAF) and inflammatory CAF (iCAF), remains a significant bottleneck in designing effective nanotherapeutic strategies. In this study, inspired by the mechanosensing nature of CAFs, we developed a peptide (AV3)-directed nanosystem to target ITGA5 receptor, a mechanoresponsive integrin that was found to be overexpressed in both myCAF and iCAF. AV3-conjugated nanoparticles (NPs) showed an efficient targeting to both CAF subtypes in vitro and in vivo after systemic administration, as confirmed by flow cytometry analyses. To functionally reprogram CAFs, we screened a library of small molecules and identified YL-109, an activator of CHIP E3 ubiquitin ligase via the aryl hydrocarbon receptor, as a potent dual modulator of myCAF and iCAF. Encapsulation of YL-109 with AV3-NPs enabled targeted re-programming of both CAF subsets in PDAC tumours in vivo , inhibiting desmoplasia, hypoxia and tumour-promoting signals. Co-treatment with CAF-targeted YL-109 NPs with gemcitabine – either alone or in combination of anti-PD-L1 – significantly enhanced the therapeutic efficacy and extended survival in PDAC-bearing mice. These effects were attributed to the induction of CHIP, reduction of collagen and enhanced infiltration of CD8 + T cells. This study contributes to the field of nanomedicine by introducing a rationally designed, dual-CAF-targeting nanosystem capable of overcoming stromal barriers in PDAC. This platform presents a new class of stroma-directed nanomedicines that integrate molecular targeting with microenvironment modulation to improve response to chemo- and immunotherapies.
Year:
2026
Retinal degeneration is the leading cause of blindness worldwide. Subretinal implantation of human retinal progenitor cells (hRPCs) has shown great promise in models of retinal degeneration for restoration of vision but is limited by extremely low (< 2%) integration into the retina. Successful integration of implanted cells requires their migration from the site of implantation into the degenerating retina. Little is known about what cues promote RPC migration in the context of the postimplantation microenvironment, such as cues presented by a biomaterial carrier. We utilized a high‐throughput assay to study the migration of hRPCs in three‐dimensional hydrogel matrices of varying chemical composition and stiffness and, with exposure to different soluble factors, to identify cues important for hRPC migration and associated cell signaling events driving migration. Collagen type I, collagen type I methacrylate, and hyaluronic acid glycidyl methacrylate gels were developed with variable stiffness. The impact of key growth factors in neural development, regeneration, and cell migration such as epidermal growth factor (EGF), fibroblast growth factor (FGF), stromal cell–derived factor (SDF), and hepatocyte growth factor (HGF) was studied using hRPCs in 2 mg/mL collagen type I gels. Migration of the hRPCs varied significantly in gels of different composition and stiffness, with higher levels of mean migration distance after 48 h in nonphoto crosslinked collagen‐based gels with higher concentrations of gel components and associated compressive moduli. In addition, the presence of SDF and HGF in collagen gels increased hRPC migration compared to media alone. Key signaling nodes correlating with hRPC migration were identified in Akt and MAPK signaltransduction pathways using bead‐based multiplex ELISA and partial least‐squares regression (PLSR) modeling. These results motivate the further exploration of material stiffness and co‐delivery of soluble factors as important design parameters in cell delivery vehicles to promote transplanted hRPC migration and successful integration into degenerating retina.
Year:
2025
Therapeutic antibody–drug conjugates (ADC) have demonstrated efficacy in cancer therapy, but adverse effects due to off-target tissue uptake and payload activity pose challenges. To address these concerns, we engineered radiation-amplified ADCs (RAMP-ADC) that release active drug payloads only upon spatially localized exposure to ionizing radiation. To further improve tumor targeting, RAMP-ADCs were developed using the bispecific antibody amivantamab, which binds to both EGFR and MET receptors, carrying either the microtubule-destabilizing monomethyl auristatin E or the topoisomerase 1 inhibitor exatecan as payloads. The constructs enhanced cytotoxic efficacy up to 2,100-fold and improved the selectivity of tumor payload delivery by up to 760-fold while minimizing systemic toxicity. RAMP-ADC treatment combined with radiation blocked colony formation in cell lines that were resistant to either radiation or amivantamab individually. RAMP-ADCs effectively blocked tumor growth in a mouse xenograft model and extended survival, whereas the bispecific antibody had little effect alone. This approach to achieve localized delivery of drug payloads has potential therapeutic value for other bispecific antibodies currently in development. Significance: Radiation amplified antibody–drug conjugates use EGFR- and MET-targeted amivantamab to deliver cytotoxic payloads to tumors and minimize off-target toxicity by chemically uncaging payload activity with ionizing radiation.
Year:
2025
Purpose: Oncogene-driven macropinocytosis fuels nutrient scavenging in some cancer types, yet whether this occurs in thyroid cancers with prominent MAPK–ERK and PI3K pathway mutations remains unclear. We hypothesized that understanding links between thyroid cancer signaling and macropinocytosis might uncover new therapeutic strategies. Experimental Design: Macropinocytosis was assessed across cells derived from papillary thyroid cancer (PTC), follicular thyroid cancer (FTC), non-malignant follicular thyroid, and aggressive anaplastic thyroid cancer (ATC), by imaging fluorescent dextran and serum albumin. The impacts of ectopic BRAF V600E and mutant RAS , genetic PTEN silencing, and inhibitors targeting RET, BRAF, and MEK kinases were quantified. Braf V600E p53 −/− ATC tumors in immunocompetent mice were used to measure efficacy of an albumin–drug conjugate comprising microtubule-destabilizing monomethyl auristatin E (MMAE) linked to serum albumin via a cathepsin-cleavable peptide (Alb-vc-MMAE). Results: FTC and ATC cells showed greater macropinocytosis than non-malignant and PTC cells. ATC tumors accumulated albumin at 8.8% injected dose per gram tissue. Alb-vc-MMAE, but not MMAE alone, reduced tumor size by >90% ( P ). ATC macropinocytosis depended on MAPK/ERK activity and nutrient signaling, and increased by up to 230% with metformin, phenformin, or inhibition of IGF1Ri in monoculture but not in vivo . Macrophages also accumulated albumin and express the cognate IGF1R ligand, IGF1, which reduced ATC responsiveness to IGF1Ri. Conclusions: These findings identify regulated oncogene-driven macropinocytosis in thyroid cancers and demonstrate the potential of designing albumin-bound drugs to efficiently treat them.
Year:
2025
Radionuclides used for imaging and therapy can show high molecular specificity in the body with appropriate targeting ligands. We hypothesized that local energy delivered by molecularly targeted radionuclides could chemically activate prodrugs at disease sites while avoiding activation in off-target sites of toxicity. As proof-of-principle, we tested whether this strategy of “ RA dionuclide i nduced D rug E ngagement for R elease” ( RAiDER ) could locally deliver combined radiation and chemotherapy to maximize tumor cytotoxicity while minimizing exposure to activated chemotherapy in off-target sites. Methods We screened the ability of radionuclides to chemically activate a model radiation-activated prodrug consisting of the microtubule destabilizing monomethyl auristatin E caged by a radiation-responsive phenyl azide (“caged-MMAE”) and interpreted experimental results using the radiobiology computational simulation suite TOPAS-nBio. RAiDER was evaluated in syngeneic mouse models of cancer using fibroblast activation protein inhibitor (FAPI) agents 99m Tc-FAPI-34 and 177 Lu-FAPI-04, the prostate-specific membrane antigen (PSMA) agent 177 Lu-PSMA-617, combined with caged-MMAE or caged-exatecan. Biodistribution in mice, combined with clinical dosimetry, estimated the relationship between radiopharmaceutical uptake in patients and anticipated concentrations of activated prodrug using RAiDER. Results RAiDER efficiency varied by 250-fold across radionuclides ( 99m Tc> 177 Lu> 64 Cu> 68 Ga> 223 Ra> 18 F), yielding up to 1.22µM prodrug activation per Gy of exposure from 99m Tc. Computational simulations implicated low-energy electron-mediated free radical formation as driving prodrug activation. Clinically relevant radionuclide concentrations chemically activated caged-MMAE restored its ability to destabilize microtubules and increased its cytotoxicity by up to 600-fold compared to non-irradiated prodrug. Mice treated with 99m Tc-FAPI-34 and caged-MMAE accumulated up to 3000× greater concentrations of activated MMAE in tumors compared to other tissues. RAiDER with 99m Tc-FAPI-34 or 177 Lu-FAPI-04 delayed tumor growth, while monotherapies did not ( P <0.03). Clinically-guided dosimetry suggests sufficient radiation doses can be delivered to activate therapeutically meaningful levels of prodrug. Conclusion This proof-of-concept study shows that RAiDER is compatible with multiple radionuclides commonly used in nuclear medicine and has the potential to improve the efficacy of radiopharmaceutical therapies to treat cancer safely. RAiDER thus shows promise as an effective strategy to treat disseminated malignancies and broadens the capability of radiopharmaceuticals to trigger diverse biological and therapeutic responses. Abstract Figure
Year:
2024
Purpose: Oncogene-driven macropinocytosis fuels nutrient scavenging in some cancer types, yet whether this occurs in thyroid cancers with prominent MAPK-ERK and PI3K pathway mutations remains unclear. We hypothesized that understanding links between thyroid cancer signaling and macropinocytosis might uncover new therapeutic strategies. Experimental Design: Macropinocytosis was assessed across cells derived from papillary thyroid cancer (PTC), follicular thyroid cancer (FTC), non-malignant follicular thyroid, and aggressive anaplastic thyroid cancer (ATC), by imaging fluorescent dextran and serum albumin. The impacts of ectopic BRAF V600E and mutant RAS, genetic PTEN silencing, and inhibitors targeting RET, BRAF, and MEK kinases were quantified. Braf V600E p53-/- ATC tumors in immunocompetent mice were used to measure efficacy of an albumin-drug-conjugate comprising microtubule-destabilizing monomethyl auristatin E (MMAE) linked to serum albumin via a cathepsin-cleavable peptide (Alb-vc-MMAE). Results: FTC and ATC cells showed greater macropinocytosis than non-malignant and PTC cells. ATC tumors accumulated albumin at 8.8% injected dose per gram tissue. Alb-vc-MMAE, but not MMAE alone, reduced tumor size by >90% (P
Year:
2024
Year:
2023
Year:
2023
Collaborators (7)
Jai Prakash
Professor and Group Leader
Radboud University Medical Center
Aaron Meyer
Associate Professor
University of California, Los Angeles
Jan Schuemann
Massachusetts General Hospital
David Lagares
Assistant Professor of Medicine
Harvard Medical School
Alejandro Bertolet
Assistant Professor
Massachusetts General Hospital
Ralph Weissleder
Harvard University
Peter Caravan
Associate Professor
Massachusetts General Hospital
Make your next move.
Prepare your application
Review drafts before you send them.